Health / WORLD

UK confirms indefinite recognition of CE-marked medical devices in Great Britain

The UK government and MHRA announced on 21 October that medical devices certified under the EU Medical Devices Regulation and In Vitro Diagnostic Regulation will be recognized indefinitely in Great Britain, while legacy directive transition timelines are extended to 2028.

Reading sizeSources ↓Share story ↗
Conceptual illustration of public health, research and connected data.Illustration
Symbolic illustration

The regulatory outcome follows a public consultation conducted earlier in 2026 that generated over 1,000 stakeholder responses. The decision avoids duplicative dual-testing burdens for manufacturers and safeguards domestic clinical supply lines across NHS hospitals.

Legacy devices certified under earlier EU directives will remain accepted until 31 December 2028, aligning Great Britain with European transition schedules. The domestic UKCA marking scheme will continue operating as a parallel, sovereign compliance route for manufacturers placing devices on the British market.

Data

Timeline

Source publication

Publication of the official consultation outcome on CE marked medical devices on 21 October 2026.

  1. · Occurred

    Government confirms indefinite CE recognition for medical devices

    Regulatory statement issued on 21 October 2026 establishing long-term recognition in Great Britain.

Methodology

The date records publication of the cited primary source. Transition timelines and regulatory frameworks are stated in the article.

Updated:

Structured coverage

Subjects and places

Subject proposals

Geographic references

Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.

  • United Kingdom · Place role: Coverage · Place type: Country or area · Location precision: Regional
    Evidence
    • Explicit preserved editorial country/region; no city or national centroid inferredwww.gov.uk ↗
Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Health

UK MHRA extends Casgevy gene-editing approval to children aged five and over

The UK Medicines and Healthcare products Regulatory Agency announced on 29 October that it has expanded the authorisation for the CRISPR-based gene therapy Casgevy to children aged five and older with severe sickle-cell disease and transfusion-dependent beta-thalassaemia.

Medicines and Healthcare products Regulatory Agency, United Kingdom1 min read Data included
Health

UK MHRA grants conditional approval for triheptanoin in rare metabolic disorders

The UK Medicines and Healthcare products Regulatory Agency approved triheptanoin (Dojolvi) on 30 October as an oral liquid for adult and paediatric patients with long-chain fatty acid oxidation disorders. The regulatory decision was granted as a conditional marketing authorisation.

Medicines and Healthcare products Regulatory Agency, United Kingdom1 min read Data included